Table V.
Lymphadenectomy | |||
---|---|---|---|
|
|||
Variable | Pelvic, n=19 | Pelvic and para-aortic, n=48 | P-value |
Median age at surgery, years (IQR) | 62 (52–70) | 62 (54–67) | 0.600 |
Histologic subtype, n (%) | |||
Endometrioid, pure | 10 (52.6) | 20 (41.7) | 0.420a |
Endometrioid, with squamous differentiation | 9 (47.4) | 28 (58.3) | |
Endometrioid, villoglandular variant | 0 (0.0) | 0 (0.0) | |
Endometrioid, ciliated cell variant | 0 (0.0) | 0 (0.0) | |
FIGO stage, n (%) | |||
IA | 3 (15.8) | 2 (4.2) | 0.100b |
IB | 12 (63.2) | 18 (37.5) | |
II | 0 (0.0) | 4 (8.3) | |
IIIA | 0 (0.0) | 3 (6.2) | |
IIIC | 4 (21.0) | 19 (39.6) | |
IVB | 0 (0.0) | 2 (4.2) | |
Grade, n (%) | |||
I | 3 (15.8) | 9 (18.8) | 0.170c |
II | 14 (73.7) | 24 (50.0) | |
III | 2 (10.5) | 15 (31.2) | |
Myometrial invasion, n (%) | |||
<1/2 | 4 (21.0) | 6 (12.5) | 0.450 |
≥1/2 | 15 (78.9) | 42 (87.5) | |
Lymphovascular invasion, n (%) | 6 (31.6) | 19 (39.6) | 0.540 |
Median tumor size, cm (IQR) | 3.5 (3.0–4.0) | 3.5 (2.5–5.3) | 0.600 |
Peritoneal cytology positive, n (%) | 2 (10.5) | 2 (4.2) | 0.320 |
Surgery, n (%) | |||
Laparoscopy | 5 (26.3) | 4 (8.3) | 0.110 |
Laparotomy | 14 (73.7) | 44 (91.7) | |
Median lymph nodes removed, n (IQR) | |||
Pelvic lymph nodes | 27 (17–32) | 26 (22–32) | 0.600 |
Paraaortic lymph nodes | 0 (0.0) | 13 (8–20) | <0.001 |
Adjuvant treatment, n (%) | |||
None | 1 (5.3) | 2 (4.2) | 0.210a |
Radiotherapy alone | 15 (78.9) | 24 (50.0) | |
Chemotherapy alone | 0 (0.0) | 2 (4.2) | |
Chemotherapy and radiotherapy | 2 (10.5) | 14 (29.1) | |
Unknown | 1 (5.3) | 6 (12.5) | |
Median follow-up time, months (95% CI) | 39 (34.29–57.40) | 39 (28.60–40.44) | 0.140 |
IQR, interquartile range; FIGO, International Federation of Gynaecology and Obstetrics; CI, confidence interval. P-values following the Bonferroni correction were a0.0125, b0.0083 and c0.0167.